We are live on ! Find out more
BBH icon

VanEck Biotech ETF

83 hedge funds and large institutions have $294M invested in VanEck Biotech ETF in 2015 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 26 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

3.59% more ownership

Funds ownership: 41.64%45.23% (+3.6%)

2% more funds holding

Funds holding: 8183 (+2)

12% less capital invested

Capital invested by funds: $333M → $294M (-$38.5M)

23% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 26

51% less call options, than puts

Call options by funds: $2.87M | Put options by funds: $5.85M

Holders
83
Holders Change
+2
Holders Change %
+2.47%
% of All Funds
2.32%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
20
Reduced
26
Closed
11
Calls
$2.87M
Puts
$5.85M
Net Calls
-$2.98M
Net Calls Change
+$1.63M

BBH Hedge Fund Activity: Q3 2015 in Review

83 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q3 2015, worth a combined $294M — down 12% from $333M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new BBH positions and 11 closed out — a net gain of 2 holders — while 20 added to existing stakes and 26 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $17.8M. The largest seller was Envestnet Asset Management, cutting an estimated $7.44M.

  • 83 institutional investors held VanEck Biotech ETF (BBH) as of Q3 2015, up from 81 in Q2 2015.
  • Funds reported $294M of VanEck Biotech ETF stock for Q3 2015, down 12% quarter-over-quarter.
  • 13 funds opened new VanEck Biotech ETF positions in Q3 2015 and 11 closed out, a net change of +2 holders.
  • The largest VanEck Biotech ETF buyer in Q3 2015 was Goldman Sachs, an estimated $17.8M added.
  • The largest VanEck Biotech ETF seller in Q3 2015 was Envestnet Asset Management, an estimated $7.44M sold.

Based on aggregated 13F filings for Q3 2015.